Global Hematopoietic Stem Cell Transplantation Market, By Type (Allogeneic HSCT, Autologous HSCT, and Others), Indication (Congenital Metabolic Defects, Hemoglobinopathies, Myelodysplastic Syndrome, Myeloproliferative Syndromes, Multiple Sclerosis, Lymphoma, Immune-Deficiency Illnesses, and Others), Application (Bone Marrow Stem Cells, Peripheral Blood Stem Cells, Umbilical Cord Stem Cells, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) – Industry Trends and Forecast to 2030.
Hematopoietic Stem Cell Transplantation Market Analysis and Size
In recent years, the Hematopoietic stem cell transplantation market is anticipated to grow rapidly during the forecast period. In 2018, the global incidence of leukemia was expected to be 437,033 new cases and almost 309,006 deaths, according to the GLOBOCAN 2018 study. According to the World Health Organization (WHO), more than 2000 cord blood hematopoietic stem cell transplants are conducted each year. The bone marrow and blood contain hematopoietic stem cells (HSCs). Hematopoietic progenitor cells are another name for them (HPCs). Hematopoietic stem cells can produce platelets, white blood cells, and red blood cells, among other blood cells. These cells are utilized to rebuild or replace a patient's hematopoietic system in the treatment of malignant (such as lymphoma and leukemia) and non-malignant (including bone marrow failure and hemoglobinopathies) disorders.
Data Bridge Market Research analyses that the global hematopoietic stem cell transplantation market which was USD 2,610.91 million in 2022, would rocket up to USD 6,327.28 million by 2030, and is expected to undergo a CAGR of 11.7% during the forecast period. This indicates that the market value. The “(Autologous HSCT” dominates the type segment of the global hematopoietic stem cell transplantation market owing to the growing demand for better diagnosis and treatment methods. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hematopoietic Stem Cell Transplantation Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Allogeneic HSCT, Autologous HSCT, and Others), Indication (Congenital Metabolic Defects, Hemoglobinopathies, Myelodysplastic Syndrome, Myeloproliferative Syndromes, Multiple Sclerosis, Lymphoma, Immune-Deficiency Illnesses, and Others), Application (Bone Marrow Stem Cells, Peripheral Blood Stem Cells, Umbilical Cord Stem Cells, and Others), End-Users (Hospitals, Specialty Clinics, Homecare, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America
|
|
Market Players Covered
|
Otsuka America Pharmaceutical, Inc. (U.S.), Akari Therapeutics, Plc (U.S.), Merck KGaA (Germany), Takeda Pharmaceutical Company Limited (Japan), Lonza (Switzerland), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), Sanofi (France), FUJIFILM Holdings Corporation (Japan), bluebird bio, Inc. (U.S.), Pluristem Therapeutics Inc. (Israel), Regen Biopharma Inc. (U.S.), Kiadis Pharma (Netherlands), Taiga Biotechnologies, Inc. (U.S.), CellGenix GmbH (Germany), Escape Therapeutics, Inc. (U.S.), Marker Therapeutics, Inc. (U.S.), Talaris Therapeutics (U.S.) among others.
|
|
Market Opportunities
|
|
Market Definition
Hematopoietic stem cell transplantation (HSCT) is a treatment option for different cancer types and other diseases. Blood stem cells and bone marrow stem cells are both sources of stem cells. Young or immature blood cells present in bone marrow are known as hematopoietic stem cells. Only a small percentage of these blood cells mature in the bone marrow and make it into the bloodstream. Peripheral blood stem cells are the cells that enter the bloodstream. Hematopoietic stem cell transplantation replaces absent, sick, or injured hematopoietic stem cells with healthy hematopoietic stem cells as a result of chemotherapy or radiation.
Global Hematopoietic Stem Cell Transplantation Market Dynamics
Drivers
- Rising Prevalence of Leukemia and Lymphoma
The rising prevalence of leukemia and lymphoma is estimated to enhance the growth of the Hematopoietic stem cell transplantation market. According to the Leukemia and Lymphoma Society's 2019 report, 176,200 people in the U.S. were diagnosed with leukemia, lymphoma, or myeloma, and 1,399,180 people lived with lymph leukemia and myeloma. The rising incidence rate is likely to fuel demand for hematopoietic stem cell transplantation (HSCT), moving the HSCT market forward.
- Growing Number of Geriatric Population
The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to getting hematopoietic stem cell transplantation, further estimated to enhance the market's growth rate
Opportunities
- Advancements in Transplantation Techniques
The field of HSCT continues to evolve, with advancements in transplantation techniques, supportive care, and donor selection strategies. These advancements have improved transplant outcomes, expanded eligibility criteria, and increased the number of patients who can benefit from HSCT. The market can capitalize on these advancements to offer innovative transplantation solutions and expand the patient pool.
- Increasing Adoption of Autologous HSCT
Autologous HSCT involves using a patient's stem cells, often collected and stored prior to high-dose chemotherapy or radiation therapy. The demand for autologous HSCT is increasing due to its potential benefits, such as reduced risk of GVHD and improved survival rates. This trend presents an opportunity for market players to expand their offerings and develop innovative solutions specifically tailored to autologous HSCT
- Growing Medical Tourism
Medical tourism, where patients travel to other countries for medical treatments, including HSCT, is on the rise. Factors such as cost advantages, availability of specialized centers, and shorter waiting times in certain regions attract patients seeking HSCT. This presents an opportunity for market players to cater to international patients and collaborate with medical tourism facilitators.
Restraints/Challenges
- Limited Availability of Suitable Donors
HSCT requires a suitable donor match for successful transplantation. However, finding a suitable donor, especially for allogeneic transplantation, can be challenging due to the need for human leukocyte antigen (HLA) compatibility. The limited availability of suitable donors can restrict the number of patients who can undergo HSCT.
- Transplant-Related Morbidity and Mortality
HSCT carries a risk of complications, including graft failure, graft-versus-host disease (GVHD), infections, organ toxicity, and relapse. These complications can lead to significant morbidity and even mortality. The risk of these adverse events can deter both patients and healthcare providers from considering HSCT as a treatment option, particularly for older or medically fragile patients.
- Lack of Standardization
HSCT involves a complex process with various steps and components, including stem cell collection, conditioning regimens, and post-transplant care. The lack of standardization in protocols, procedures, and supportive care practices can lead to variability in outcomes and hinder the widespread adoption of HSCT.
- Long-Term Follow-up and Survivorship Care
HSCT survivors require long-term follow-up care, including monitoring for late effects, managing chronic graft-versus-host disease (GVHD), and addressing psychosocial and quality-of-life issues. The provision of comprehensive survivorship care can be challenging due to limited resources, coordination of multidisciplinary care, and addressing the unique needs of HSCT survivors.
This hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hematopoietic stem cell transplantation market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth
Recent Developments
- In August 2021, Magenta Biosciences, announced a spin-off collaboration with bluebird bio to develop HSPC-based gene therapies for genetic diseases. The specific date of this announcement is not provided.
- In July 2020, Gamida Cell announced positive results from a Phase 3 clinical trial of NiCord, an investigational product. The trial showed improved overall survival and reduced time to neutrophil engraftment compared to standard umbilical cord blood transplantation.
This global hematopoietic stem cell transplantation market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global hematopoietic stem cell transplantation market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Hematopoietic Stem Cell Transplantation Market Scope
The global hematopoietic stem cell transplantation market is categorized into five notable segments, which are based on the basis of product, sample, mode of purchase, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Allogeneic HSCT
- Autologous HSCT
- Others
Indication
- Congenital Metabolic Defects
- Hemoglobinopathies
- Myelodysplastic Syndrome
- Myeloproliferative Syndromes
- Multiple Sclerosis
- Lymphoma
- Immune-Deficiency Illnesses
- Others
Application
- Bone Marrow Stem Cells
- Peripheral Blood Stem Cells
- Umbilical Cord Stem Cells
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Global Hematopoietic Stem Cell Transplantation Market Regional Analysis/Insights
The global hematopoietic stem cell transplantation market is analysed and market size insights and trends are provided by country, type, indication, application, end-users and distribution channel as referenced above.
The countries covered in the hematopoietic stem cell transplantation market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
North America dominates the hematopoietic stem cell transplantation market because of the strong base of healthcare facilities, the strong presence of major players in the market, the extraordinary healthcare infrastructure, and the large pool of patients.
Asia-Pacific is expected to witness significant growth during the forecast period from 2023 to 2030 due to the increase in government initiatives to promote healthcare, the rising health awareness among the people and growing demand for advanced medical technology for skin care, the large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and up-stream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Hematopoietic Stem Cell Transplantation Market Share Analysis
The global hematopoietic stem cell transplantation market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the global hematopoietic stem cell transplantation market
Some of the major players operating in the global hematopoietic stem cell transplantation market are:
- Otsuka America Pharmaceutical, Inc. (U.S.)
- Akari Therapeutics, Plc (U.S.)
- Merck KGaA (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
- Lonza (Switzerland)
- GlaxoSmithKline plc (U.K.)
- Novartis AG (Switzerland)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Sanofi (France)
- FUJIFILM Holdings Corporation (Japan)
- bluebird bio, Inc. (U.S.)
- Pluristem Therapeutics Inc. (Israel)
- Regen Biopharma Inc. (U.S.)
- Kiadis Pharma (Netherlands)
- Taiga Biotechnologies, Inc. (U.S.)
- CellGenix GmbH (Germany)
- Escape Therapeutics, Inc. (U.S.)
- Marker Therapeutics, Inc. (U.S.)
- Talaris Therapeutics (U.S.)
SKU-